Sign In
Buy SYGGF
$0.0001
+0 (+0%)
At Close: Jun 22, 2026
Synairgen shares stay tradeable post-delisting, as top investor waives restrictions
02:32am, Thursday, 03'rd Apr 2025
Synairgen PLC (AIM:SNG, OTC:SYGGF), a biotech company developing an experimental inhaled treatment for respiratory infections, says its shares will remain freely tradeable - even after its recent move
Synairgen becomes the latest company to eye the AIM exit door
04:02am, Tuesday, 11'th Mar 2025
Synairgen PLC (AIM:SNG, OTC:SYGGF) is set to become the latest in a growing wave of smaller companies leaving London's AIM market after struggling to lock down fresh investment. The biotech firm, whi
Synairgen CEO on funding phase 2 trial for SNG001 - ICYMI
01:33am, Saturday, 21'st Dec 2024
Synairgen PLC (AIM:SNG, OTC:SYGGF) chief executive Richard Marsden talked with Proactive about the company's recent fundraising efforts to support a phase II clinical trial. The study aims to test SNG
Synairgen backer ready to pump £18-£19 million into phase II trial
03:02am, Friday, 20'th Dec 2024
Synairgen PLC (AIM:SNG, OTC:SYGGF), the respiratory-focused biopharmaceutical company, has announced plans to raise up to £25 million to fund the development of SNG001, its investigational inhaled i
Synairgen making substantial progress towards phase II trial
03:04am, Thursday, 26'th Sep 2024
Synairgen PLC (AIM:SNG, OTC:SYGGF) said it has made 'substantial progress' preparing for a phase II trial of its lead asset, SNG001, which is being developed to treat high-risk patients with severe vi
Synairgen appoints inhaled drug development expert as chairman
03:21am, Wednesday, 18'th Sep 2024
Synairgen PLC (AIM:SNG, OTC:SYGGF) chairman Simon Shaw will retire at next month's annual shareholder meeting, to be replaced by Mark Parry-Billings, who he called "a world class inhaled drug developm
Synairgen making plans for phase II trial
02:45am, Thursday, 27'th Jun 2024
Synairgen PLC (AIM:SNG, OTC:SYGGF) said it is on the "verge of embarking" on a phase II trial of SNG001, for severe viral lung infection. The focus will be on patients who are mechanically ventilated
Synairgen appoints new CFO as incumbent bows out after nearly 20 years
02:47am, Wednesday, 11'th Oct 2023
Synairgen PLC (AIM:SNG, OTC:SYGGF) said Joseph Colliver will succeed John Ward as chief financial officer effective November 6. Colliver comes to Synairgen with experience in senior finance and non-
Synairgen hires full-time chief medical officer as drug development ramps up
02:27am, Tuesday, 03'rd Oct 2023
Synairgen PLC (AIM:SNG, OTC:SYGGF) has appointed seasoned pharmaceutical physician and drug developer Dr. Marcin Mankowski as chief medical officer, effective immediately.
Banks and pharmaceutical companies lead in London, while Synairgen, Morses shares tumble
12:42pm, Monday, 21'st Feb 2022 MarketWatch
London stocks were under pressure on Monday, as investors got whipsawed by updates on the Ukraine-Russia crisis. Syanirgen and Morses were big movers to the
Synairgen shares plunge as Covid-19 treatment trial fails
09:27am, Monday, 21'st Feb 2022 Share Cast
Synairgen announced on Monday that the international phase 3 trial of its SNG001 antiviral inhalation in patients hospitalised with Covid-19 did not meet its primary or key secondary endpoints.
Synairgen stock sinks 85% as COVID-19 treatment misses trial targets
08:47am, Monday, 21'st Feb 2022 ForexTV
Synairgen stock sinks 85% as COVID-19 treatment misses trial targets Read Full Story The post Synairgen stock sinks 85% as COVID-19 treatment misses trial targets appeared first on ForexTV .
Synairgen Shares Plunge as Covid-19 Treatment Misses Trial Targets
08:42am, Monday, 21'st Feb 2022 MarketWatch
By Joe Hoppe Shares in Synairgen PLC plummeted 85% on Monday after the company said that a Phase 3 trial of its inhaled treatment for Covid-19 failed to meet
Synairgen plc 2021 Q2 - Results - Earnings Call Presentation
09:10pm, Wednesday, 15'th Dec 2021 Seeking Alpha
This research report will give you deep insights about the Corona Virus Treatment Market and it will also help you in strategic decision making. The final research document is an exhaustive document comprising of 150 pages. All our reports are
